Company
Amicus Therapeutics, Inc.
Headquarters: Cranbury, NJ, United States
Founded: February 4, 2002
Employees: 496
CEO: Mr. John F. Crowley
Market Cap
$2.88 Billion
USD as of Jan. 1, 2025
Amicus Therapeutics, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Financials
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | $493.7 M |
| EBITDA | $23.1 M |
| Gross Profit TTM | $444.2 M |
| Profit Margin | -21.21% |
| Operating Margin | 17.53% |
| Quarterly Revenue Growth | 36.70% |
Stocks & Indices
Amicus Therapeutics, Inc. has the following listings and related stock indices.
Stock: NASDAQ: FOLD wb_incandescent
Stock: BMV: FOLD wb_incandescent
Stock: FSX: AM6 wb_incandescent
Key People
John Crowley (Chairman and Chief Executive Officer) Bradley Campbell (President and Chief Operating Officer) Daphne Quimi (Chief Financial Officer) David Clark (Chief People Officer)